Eyenovia, Inc.

EYEN · NASDAQ

$7.56 +3.99% (+$0.29)

Valuation

N/A

EV/EBITDA N/A

P/S N/A

P/B N/A

Growth

N/A

Rev. growth N/A

FCF growth N/A

Book val. growth N/A

Profitability

N/A

Net margin N/A

Op. margin N/A

FCF margin N/A

Quality

N/A

ROE N/A

ROA N/A

Asset turnover N/A

Debt

N/A

Current ratio N/A

Int. coverage N/A

Net debt/EBITDA N/A

Stability

87 /100

Stable

Beta 1.00x

EPS volatility N/A

Profitable years N/A

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o EYEN

Online

O podjetju

Eyenovia, Inc. (EYEN) is a biotechnology company focused on the development and commercialization of ophthalmic drugs and technologies. The company specializes in an innovative approach to treat eye conditions such as glaucoma, myopia, and pupil dilation. Their drugs are designed to improve efficacy and reduce uncomfortable side effects associated with traditional ophthalmic medications. Eyenovia aims to provide patients and eye care professionals with better and more advanced medical solutions for eye-related issues. Investing in shares of Eyenovia, Inc. can present an attractive opportunity for investors interested in innovative medical fields with the potential to enhance the quality of life for patients with eye-related conditions.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Biotechnology

CEO

Michael M. Rowe

Employees

Headquarters

New York City

⌘ K

StockBot Live

Tržne razmere Wall Street

Wall Street v padcu zaradi rasti donosnosti obveznic

S&P 500 padel -0.21%, Dow -0.44%. Donosnosti obveznic blizu 5 % so izničile rast tehnološkega sektorja.

Vprašajte o tem

StockBot pozna 80,000+ delnic po vsem svetu